Are statins 'IDEAL' for non-alcoholic fatty liver disease?

被引：30

作者：

Athyros, Vasilios G. ^{[1
]}

Katsiki, Niki ^{[1
]}

Karagiannis, Asterios ^{[1
]}

Mikhailidis, Dimitri P. ^{[2
]}

机构：

[1] Aristotle Univ Thessaloniki, Hippokration Hosp, GR-54006 Thessaloniki, Greece

[2] UCL, Sch Med, London NW3 2QG, England

来源：

CURRENT MEDICAL RESEARCH AND OPINION | 2014年 / 30卷 / 02期

关键词：

Cardiovascular disease; Clinical benefit; High dose; Non-alcoholic fatty liver disease; Statin treatment; Transaminases; LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; POST-HOC ANALYSIS; METABOLIC SYNDROME; ALANINE AMINOTRANSFERASE; MULTIFACTORIAL TREATMENT; CLINICAL-SIGNIFICANCE; CARDIOVASCULAR RISK; GREEK ATORVASTATIN; EVALUATION GREACE;

D O I：

10.1185/03007995.2013.855192

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and cause of elevated serum liver enzyme activities in the developed world1. Obesity, diabetes mellitus (DM), and dyslipidaemia, common components of the metabolic syndrome (MetS), are frequently associated with NAFLD; 75-100% of patients with MetS or DM have NAFLD2. NAFLD is characterized by hepatic triglyceride (TG) infiltration in the absence of alcohol abuse or chronic liver disease1. NAFLD includes a spectrum of conditions varying from steatosis to steatosis with inflammation [steatohepatitis (NASH)], necrosis, fibrosis or cirrhosis that rarely progresses to hepatocellular carcinoma3. NAFLD and NASH are the hepatic manifestations of MetS and are associated with increased cardiovascular disease (CVD) risk4. Most NAFLD/NASH patients die from CVD rather than from liver disease4,5. There is no universally accepted treatment for NAFLD1-5.

引用

页码：229 / 231

页数：3

共 23 条

[1] Nonalcoholic fatty liver disease [J].

Brunt, Elizabeth M. ;

Wong, Vincent W. -S. ;

Nobili, Valerio ;

Day, Christopher P. ;

Sookoian, Silvia ;

Maher, Jacquelyn J. ;

Bugianesi, Elisabetta ;

Sirlin, Claude B. ;

Neuschwander-Tetri, BrentA. ;

Rinella, Mary E. .

NATURE REVIEWS DISEASE PRIMERS, 2015, 1

[2] Do we need to consider inflammatory markers when we treat atherosclerotic disease? [J].

Athyros, Vasilios G. ;

Kakafika, Anna I. ;

Karagiannis, Asterios ;

Mikhailidis, Dimitri P. .

ATHEROSCLEROSIS, 2008, 200 (01) :1-12

[3] Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study [J].

Athyros, Vasilios G. ;

Mikhailidis, Dimitri P. ;

Didangelos, Triandafillos P. ;

Giouleme, Olga I. ;

Liberopoulos, Evangelos N. ;

Karagiannis, Asterios ;

Kakafika, Anna I. ;

Tziomalos, Konstantinos ;

Burroughs, Andrew K. ;

Elisaf, Moses S. .

CURRENT MEDICAL RESEARCH AND OPINION, 2006, 22 (05) :873-883

[4] Statins and nonalcoholic fatty liver disease: a bright future? [J].

Athyros, Vasilios G. ;

Katsiki, Niki ;

Karagiannis, Asterios ;

Mikhailidis, Dimitri P. .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (09) :1089-1093

[5] Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? [J].

Athyros, Vasilios G. ;

Tziomalos, Konstantinos ;

Daskalopoulos, Georgios N. ;

Karagiannis, Asterios ;

Mikhailidis, Dimitri P. .

ANNALS OF MEDICINE, 2011, 43 (03) :167-171

[6] Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis [J].

Athyros, Vasilios G. ;

Tziomalos, Konstantinos ;

Gossios, Thomas D. ;

Griva, Theodora ;

Anagnostis, Panagiotis ;

Kargiotis, Konstantinos ;

Pagourelias, Efstathios D. ;

Theocharidou, Eleni ;

Karagiannis, Asterios ;

Mikhailidis, Dimitri P. .

LANCET, 2010, 376 (9756) :1916-1922

[7] Pleiotropic Effects of Statins - Clinical Evidence [J].

Athyros, Vasilios G. ;

Kakafika, Anna I. ;

Tziomalos, Konstantinos ;

Karagiannis, Asterios ;

Mikhailidis, Dimitri P. .

CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (05) :479-489

[8] Safety and impact in cardio vascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study [J].

Athyros, Vassilios G. ;

Giouleme, Olga ;

Ganotakis, Emmanouel S. ;

Elisaf, Moses ;

Tziomalos, Konstantinos ;

Vassiliadis, Themistoklis ;

Liberopoulos, Evangelos N. ;

Theocharidou, Eleni ;

Karagiannis, Asterios ;

Mikhailidis, Dimitri P. .

ARCHIVES OF MEDICAL SCIENCE, 2011, 7 (05) :796-805

[9]

Athyros VG, 2011, CURR VASC PHARMACOL, V9, P647

[10] Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention - The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study [J].

Athyros, VG ;

Papageorgiou, AA ;

Mercouris, BR ;

Athyrou, VV ;

Symeonidis, AN ;

Basayannis, EO ;

Demitriadis, DS ;

Kontopoulos, AG .

CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (04) :220-228

← 1 2 3 →